NATERA, INC.
In the published model solve dated 2026-Q2, anchored at $274.64, NATERA, INC. (NTRA) is priced for today's economics sustained for ~21.6 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Natera runs a single business, the development and commercialization of DNA-based molecular testing services, and the molecular-residual-disease test Signatera now carries the story: Q1 2026 revenue reached $697 million, up 39% year over year, on the first quarter the company ever shipped more than one million units. [Source: Natera Q1 2026 earnings release, May 2026] • The clearest risk is that the company still loses money: operating income ran roughly negative $324 million on a trailing bas
Is NTRA overvalued? See what's priced in →
738 institutional managers reported holding NTRA in 13F filings for the quarter ended 2026-03-31. Together they hold about 85% of the company; the top 10 hold 41%. 75 opened new positions that quarter. Held by Vanguard Group, T. Rowe Price, BlackRock, among others. On the short side, 4.3M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
NTRA's share count grew 60.7% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at NTRA over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
NTRA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | +16.0% | -14.6% |
| 2023-11-10 | +4.0% | +30.2% |
| 2024-03-01 | +13.3% | +8.3% |
| 2024-05-11 | +9.7% | +6.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
NTRA's latest 8-K filings: 2026-08-06 (items 2.02, 9.01); 2026-07-06 (items 5.02); 2026-06-16 (items 5.02, 5.07, 9.01); 2026-06-05 (items 5.02, 9.01); 2026-05-07 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.